3//SEC Filing
Onyx Therapeutics, Inc. 3
Accession 0000899243-18-017437
CIK 0001645666other
Filed
Jun 19, 8:00 PM ET
Accepted
Jun 20, 6:42 PM ET
Size
7.0 KB
Accession
0000899243-18-017437
Insider Transaction Report
Form 3
Onyx Therapeutics, Inc.
10% Owner
Holdings
Series A Redeemable Convertible Preferred Stock
→ Common Stock (1,121,384 underlying)
AMGEN INC
10% Owner
Holdings
Series A Redeemable Convertible Preferred Stock
→ Common Stock (1,121,384 underlying)
Footnotes (3)
- [F1]As more fully described in the Issuer's Registration Statement on Form S-1 (Registration No. 333-225194), upon completion of the Issuer's initial public offering, each share of Series A redeemable convertible preferred stock will automatically convert into one share of the Issuer's common stock.
- [F2]These shares are owned directly by Onyx Therapeutics, Inc., or Onyx, an indirect wholly-owned subsidiary of Amgen Inc., or Amgen. Amgen may be deemed to beneficially own securities held by Onyx, but disclaims beneficial ownership of the securities reported herein except to the extent of its pecuniary interest therein.
- [F3]10% beneficial ownership is calculated in accordance with SEC rules based on the number of shares of the Issuer's common stock outstanding on the date hereof and the conversion of only the reporting person's shares of preferred stock. Upon the closing of the Issuer's initial public offering, the shares held by the reporting persons will represent less than 10% beneficial ownership of the outstanding shares of common stock.
Documents
Issuer
Kezar Life Sciences, Inc.
CIK 0001645666
Entity typeother
IncorporatedDE
Related Parties
1- filerCIK 0001744260
Filing Metadata
- Form type
- 3
- Filed
- Jun 19, 8:00 PM ET
- Accepted
- Jun 20, 6:42 PM ET
- Size
- 7.0 KB